Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028082 | 1.00 | CYP19A1 (0.46) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL11729706 | 0.95 | HTR6 (0.43) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL627090 | 0.89 | HTR6 (0.50) | IDO1 | |
| SCHEMBL2321934 | 0.83 | CYP19A1 (0.46) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL16034237 | 0.80 | CYP19A1 (0.49) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL7898127 | 0.80 | IDO1 (0.52) | CYP19A1TBXAS1IDO1SIGMAR1 | |
| SCHEMBL16061146 | 0.78 | HTR2A (0.42) | — | |
| SCHEMBL31028096 | 0.78 | KDM4C (0.44) | — | |
| SCHEMBL13592999 | 0.78 | ACHE (0.43) | SIGMAR1 | |
| SCHEMBL11732016 | 0.78 | HTR6 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3354649-A1 | OXA SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN MEDICINES | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
| US-4065569-A | Use of 2-imidazolines as hypoglycemic agents | SCHERING CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-3992403-A | 2-Imidazolines and their use as hypoglycemic agents | SCHERING CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | CYP19A1 3414/4885TBXAS1 564/4885IDO1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.